Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach

Applied Immunohistochemistry and Molecular Morphology

Volumn 15, Issue 1, 2007, Pages 19-30

  Papay, Judit ^a   Krenacs, Tibor ^a   Moldvay, Judit ^a   Stelkovics, Eva ^b   Furak, Jozsef ^c   Molnar, Bela ^a   Kopper, Laszlo ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

catenin deregulation; Brain metastasis; Nonsmall cell lung cancer; Tissue microarray

Indexed keywords

BETA CATENIN; CASPASE 3; CASPASE 9; CD44V6 ANTIGEN; COLLAGEN TYPE 17; CYCLIN D1; CYCLIN D3; PROTEIN P16; PROTEIN P53; SYNDECAN 1;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BRAIN METASTASIS; CANCER GROWTH; CANCER SURVIVAL; CANCER TISSUE; CELL ADHESION; CELL CYCLE REGULATION; CELL GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOWN REGULATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LUNG NON SMALL CELL CANCER; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY;

ADULT; AGED; APOPTOSIS; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS;

EID: 34247580306     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000213143.32030.f5     Document Type: Article

References (75)

1. Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan. A Japanese lung cancer registry study. Lung Cancer. 2005;50:227-234.
2. Janout V, Siroky P, Novak J, et al. Lung cancer incidence in the Czech Republic: a time-trend study. 2004;27:376-379.
3. Stang A, Pohlabeln H, Muller KM, et al. Diagnostic agreement of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52:29-36.
4. Nonomura A, Mizukami Y, Shimizu J, et al. Clinicopathological study of primary malignant tumors of the lung: an analysis of 993 tumors resected at the Kanazawa University Hospital between 1979-1993. J Surg Oncol. 1995;58:5-11.
5. Harpole DH, Herndon JE, Wolfe WG, et al. A prognostic model of recurrence and death in stage I NSCLC utilizing presentation, histopathology and oncoprotein expression. Cancer Res. 1995;55:51-56.
6. Casson AG, McCuaig S, Craig I, et al. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer: a prospective study. J Surg Oncol. 1994;56:13-20.
7. Ishida H, Irie K, Itoh T, et al. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer. 1997;80:1034-1045.
8. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non small cell lung carcinoma. N Eng J Med. 1993;329:690-694.
9. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen A: a favorable prognostic factor in non-small cell lung cancer. New Engl J Med. 1991;324:1084-1090.
10. Saad RS, Liu YL, Han H, et al. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004;35:3-7.
11. Tanaka F, Yanagihara K, Otake Y, et al. Prognostic factors in resected pathologic (p-) stage IIIA-N2, non-small-cell lung cancer. Ann Surg Oncol. 2004;11:612-618.
12. Slebos RJC, Kibbelaar REO, Dalesio A, et al. K-RAS oncogene activation as a prognostic marker in adenocarcinoma of the lung. New Engl J Med. 1990;10:561-565.
13. Moldvay J, Scheid P, Wild P, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res. 2000;6:1125-1134.
14. Takahashi T, Nau MM, Chiba I, et al. P53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246:491-499.
15. Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patient's survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004;91:2018-2025.
16. Kern JA, Slebos RJC, Top B, et al. C-erbB2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest. 1994;93:516-520.
17. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15:28-32.
18. Caputi M, Esposito V, Baldi A, et al. p21waf1/cip1mda-6 expression in non-small-cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol. 1998;18:213-217.
19. Kanters SDJM, Lammers JWJ, Voest EE. Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J. 1995;8:1389-1397.
20. Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer. 2004;90:1555-1562.
21. Laga AC, Zander DS, Cagle PT. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non-small cell lung cancer. Arch Pathol Lab Med. 2005;129:1113-1117.
22. Vargas SO, Leslie KO, Vacek PM, et al. Estrogen-receptor-related protein p29 in primary non-small cell lung carcinoma. Cancer. 1998;82:1495-1500.
23. Strauss GM. Prognostic markers in resectable non-small cell lung cancer. Haematol/Oncol Clin North Am. 1997;11:409-434.
24. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98:13790-13795.
25. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001;98:13784-13789.
26. Sun Z, Yang P, Aubry MC, et al. Can gene expression profiling predict survival for patients with squamous cell carcinoma of the lung? Mol Cancer. 2004;3:35. Available at: Biomed Central Ltd. Accessed December 03, 2004.
27. Konnonen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
28. Kallioniemi O-P, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Gen. 2001;10:657-662.
29. Marczinovits I, Krenacs T, Stelkovics E, et al. Development of monoclonal antibodies for detecting hemidesmosomal proteins, Bullous Pemphigoid antigen 22 (BPAG2) and alpha-6 integrin: expression of BPAG2 in epidermal malignancies. Cancer Detect Rev. 2004;28(suppl 1):S-61.
30. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002;161:1557-1565.
31. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95:14863-14868.
32. Junker K. Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer. 2001;33(suppl 1):S17-S24.
33. Niklinski J, Niklinska W, Laudanski J, et al. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer Suppl. 2001;2:S53-S58.
34. Kopper L, Timar J. Genomics of lung cancer may change diagnosis, prognosis and therapy. Path Oncol Res. 2005;11:5-10.
35. Petersen I. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001;98:13784-13789.
36. Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci. 2006;63:449-468.
37. Kato Y, Hirano T, Yoshida K, et al. Frequent loss of E-cadherin and/or catenins in intrabronchial lesions during carcinogenesis of the bronchial epithelium. Lung Cancer. 2005;48:323-330.
38. Awaya H, Takeshima Y, Amatya VJ, et al. Loss of expression of E-cadherin and beta-catenin is associated with progression of pulmonary adenocarcinoma. Pathol Int. 2005;55:14-18.
39. Bremnes RM, Veve R, Hirsch FR, et al. The E-Cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer. 2002;36:115-124.
40. Xu HT, Wang L, Lin D, et al. Abnormal beta-catenin and reduced axin expression are associated with poor differentiation and progression in non-small-cell lung cancer. Am J Clin Pathol. 2006;125:534-541.
41. Brembeck FH, Rosario M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of B-catenin. Curr Opin Gen Develop. 2006;16:51-59.
42. Tamura M, Ohta Y, Tsunezuka Y, et al. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130:740-745.
43. Franzke C-W, Tasanen K, Schumann H, et al. Collagenous transmembrane proteins: collagen XVII as a prototype. Matrix Biol. 2003;22:299-309.
44. Yamada T, Endo R, Tsukagoshi K, et al. Aberrant expression of a hemidesmosomal protein, bullous pemphigoid antigen 2, in human squamous cell carcinoma. Lab Invest. 1996;75:589-600.
45. Iizasa T, Chang H, Suzuki M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res. 2004;10:5361-5366.
46. Dohadwala M, Batra RK, Luo J, et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem. 2002;277:50828-50833.
47. Wimmel A, Kogan E, Ramaswamy A, et al. Variant expression of CD44 in preneoplastic lesions of the lung. Cancer. 2001;92:1231-1236.
48. Lee LN, Kuo SH, Lee YC, et al. CD44 splicing pattern is associated with disease progression in pulmonary adenocarcinoma. J Formos Med Assoc. 2005;104:541-548.
49. Milas I, Komaki R, Hachiya T, et al. Epidermal growth factor receptor, cyclooxigenase-2, and Bax expression in the primary nonsmall cell lung cancer and brain metastases. Clin Cancer Res. 2003;9:1070-1076.
50. Toyoshima E, Ohsaki Y, Nishigaki Y, et al. Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor. Lung Cancer. 2001;31:193-202.
51. Linnerth NM, Sirbovan K, Moorehead RA. Use of transgenic mouse model to identify markers of human lung tumors. Int J Cancer. 2005;114:977-982.
52. Shah L, Walter KL, Borczuk AC, et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with non-small cell lung carcinoma. Cancer. 2004;101:1632-1638.
53. Anttonen A, Leppa S, Ruotsalainen T, et al. Pretreatment serum syndecan-1 levels and outcome in non-small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2003;41:171-177.
54. Volm M, Koomagi R. Relevance of proliferative and pro-apoptotic factors in non-small cell lung cancer for patient survival. Br J Cancer. 2000;82:1747-1754.
55. Shingal S, Vachani A, Anti-Ozerkis D, et al. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res. 2005;11:3974-3986.
56. Keum JS, Kong G, Yang SC, et al. Cyclin D1 overexpresson is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer. 1999;81:127-132.
57. INK4A and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol. 1999;188:351-360.
58. Au NHC, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol. 2004;204:101-109.
59. Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Ann Rev Physiol. 2002;61:249-255.
60. Steels E, Paesmans M, Bergmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Resp J. 2001;18:705-719.
61. Au NHC, Gown AM, Cheang M, et al. p63 expression in lung carcinoma. Appl Immunohistochem Mol Morphol. 2004;12:240-247.
62. Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INKa expression in resected non-small cell lung tumors. Cancer Res. 1996;56:3415-3420.
63. Sakaguchi M, Fujii Y, Hirabayashi H, et al. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer. 1996;65:442-445.
64. Shapiro GI, Edwards CD, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995;55:505-509.
65. Hommura F, Dosaka-Akita H, Kinoshita I, et al. Predictive value of expression of p16INKa, retinoblastoma and p53 proteins for the prognosis of non-small cell lung cancers. Br J Cancer. 1999;81:696-701.
66. Leversha MA, Fielding P, Watson S, et al. Expression of p53, pRB and p16 in lung tumors: a validation study of tissue microarrays. J Pathol. 2003;200:610-619.
67. Gessner C, Liebers U, Kuhn H, et al. BAX and p16INK4a are independent positive prognostic markers for advanced tumor stage of non-small cell lung cancer. 2002;19:134-140.
68. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer. 2001;34:207-218.
69. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. 2003;41:S29-S42.
70. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst. 2005;97:643-655.
71. Dacic S, Flanagan M, Cieply K, et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. 2006;125:860-865.
72. Italiano A, Vandenbos FB, Otto J, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small cell lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol. 2006;17:981-985.
73. Schwab R, Pinter F, Moldvay J, et al. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. J Clin Oncol. 2005;23:7736-7738.
74. Shivapurkar N, Reddy J, Preet MC, et al. Apoptosis and lung cancer: a review. J Cell Biochem. 2003;88:885-989.
75. Takata T, Tanaka F, Yamada T, et al. Clinical significance of caspase-3 expression in pathologic-stage I non-small cell lung cancer. Int J Cancer. 2001;96(suppl):54-60.